Assuntos
Micose Fungoide/diagnóstico , Micose Fungoide/terapia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , Urticária/diagnóstico , Negro ou Afro-Americano , Anti-Inflamatórios/uso terapêutico , Anticarcinógenos/uso terapêutico , Antimetabólitos Antineoplásicos/uso terapêutico , Bexaroteno , Biópsia por Agulha , Diagnóstico Diferencial , Educação Médica Continuada , Eosinofilia/diagnóstico , Eosinofilia/terapia , Feminino , Humanos , Antígeno Ki-1/análise , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Prednisona/uso terapêutico , Prurido/diagnóstico , Prurido/terapia , Tetra-Hidronaftalenos/uso terapêutico , Urticária/terapiaRESUMO
From the first allergen immunotherapy proposed in the early 1900s to the present day, numerous studies have proven the efficacy of allergen immunotherapy for the treatment of allergic rhinitis, allergic conjunctivitis, allergic asthma and stinging insect hypersensitivity. The major risk, however small, with allergen immunotherapy is anaphylaxis. There has been considerable interest and debate regarding risk factors for immunotherapy reactions (local and systemic) and interventions to reduce the occurrence of these reactions. One of these interventions that is especially debated regards dose adjustment for various reasons, but in particular for local reactions. In this review, we discuss the safety of immunotherapy and provide a comprehensive review of the literature regarding immunotherapy schedules and doses.
